spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  protein kinase inhibitor 

 HSMN NewsFeed - 7 Sep 2022
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Aug 2022
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Oct 2007
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Sep 2007
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2007
Poniard Pharmaceuticals Appoints Ronald A. Martell President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2007
Poniard Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase 3 Trial of Picoplatin for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Poniard Announces Positive Interim Survival Results from Ongoing Phase 2 Trial of Picoplatin for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Conditions
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Jul 2006
Poniard Pharmaceuticals Appoints Alan B. Glassberg, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jun 2006
Poniard Pharmaceuticals Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2006
NeoRx Corporation (Poniard Pharmaceuticals) Announces Treatment of First Patient With Picoplatin in Phase 1/2 Front-Line Prostate Cancer Trial
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
protein kinase inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.